Abstract
treatment, proteinuria had decreased from 8±1.8 to Subjects and methods 5 .2±1.3 g/day (P<0.05). Four weeks after captopril discontinuation, proteinuria rose to 7.3±1.7 g/day Patients (P<0.05). A marked variability in the antiproteinuric response was observed, ranging from 0 to 85% with Eleven patients with biopsy-proven MGN were included in respect to baseline values. No correlation between the study. The main characteristics of the patients are expressed in Table 1 . Date of renal biopsy was considered as decrease in proteinuria and baseline urinary C5b-9 the onset of the disease. All the patients had normal blood levels was observed. Several patients with elevated pressure; two of them were taking calcium-channel blockers urinary C5b-9 levels had captopril-induced decrease in because of previous moderate arterial hypertension. None of proteinuria.
them had previously been treated with ACE inhibitors, Patients were evaluated every 4 weeks on five occasions Pearson correlation coefficient. Significance was considered when P<0.05. (−4 week, baseline, +4 week, +8 week and +12 week). At each examination, body weight and blood pressure were measured and blood was drawn for general biochemistry.
Results
Urinary protein, creatinine, sodium, potassium, and urea were measured in a 24-h urine sample, which was collected the day before the visit. At baseline and at +8 week visits, Patients with MGN had significantly higher baseline freshly voided urine samples for C5b-9, creatinine, and urinary levels of C5b-9 than the control group of protein were obtained. Freshly voided urine samples for the 14 healthy volunteers (89±23 ng/mg UCr versus same parameters were also obtained from 14 normal controls, 3.7±1.4 ng/mg UCr, P<0.001). Proteinuria decreased with normal blood pressure and without any known renal from 8±1.8 to 5.2±1.3 g/day after 8 weeks of captopdisease.
ril treatment (P<0.05) ( Table 2 ). Four weeks after Urinary C5b-9 levels were measured using ELISA kits captopril withdrawal (+12 week, Table 2 ), proteinuria (Quidal Labs, La Jolla, CA, USA). Wells were lined with a significantly increased to 7.3±1.7 g/day (P<0.05 with mouse monoclonal antibody against human C5b-9. Urine samples were added to the wells and incubated for 1 h. The respect to values at +8 week). There were no significwells were washed five times and a goat antibody against ant changes in other clinical or biochemical parameters C6-C7 complement components was added. After 1 h of throughout the study. incubation, the wells were again washed five times.
Mean proteinuria decrease (% of proteinuria reducChromogen was added to the wells and the light absorbance tion at +8 week with respect to baseline values) was at 405 nm was measured after 30 min. A standard curve was 32±8.8%. However, proteinuria decrease was not unigenerated using known amounts of C5b-9 provided with the form (Figure 1 ). Captopril-induced proteinuria kit. Inter-and intra-assay variabilities for urinary C5b-9 decrease did not show any correlation with the clinical were 7.5% and 5.5% respectively. C5b-9 levels are expressed or biochemical parameters at baseline. Similarly, no as nanograms per milligram of urinary creatinine (ng/mg correlation was found between proteinuria decrease UCr). and blood pressure changes, urinary urea excretion or urinary sodium throughout captopril treatment.
Statistical analysis
Proteinuria decrease was also independent of baseline urinary C5b-9 levels. As is shown in Figure 1 , some All data are presented as mean±standard error. Evaluation patients with high levels of urinary C5b-9 showed an of statistical significance was performed with Wilcoxon test antiproteinuric response to captopril, whereas in other for paired data and Mann-Whitney test for unpaired data.
Correlations between variables were calculated using the cases proteinuria decrease was poor or absent. On the MGN [6] [7] [8] [9] [10] [11] [12] 15] . However, the significance of C5b-9 urinary is unclear. Increased urinary C5b-9 excretion is not specific for MGN; patients with heavy proteinuria secondary to diabetic nephropathy, focal glomerulosclerosis and other renal diseases frequently show increased urinary C5b-9 [9, 12] . In some studies no correlation was found between the magnitude of proteinuria and the urinary C5b-9 levels [8, 11] , while others have shown a positive correlation between both variables [9, 12] . We have found that C5b-9 levels showed a significant correlation with the magnitude of proteinuria ( Figure 2 ). Several studies have reported an antiproteinuric effect of ACE inhibitors in MGN; the magnitude of proteinuria reduction ranged between 27 and 59% of the baseline values [1] [2] [3] [4] . In the present study we observed a significant decrease in proteinuria induced by captopril; mean proteinuria decrease was 32±8.8% with respect to baseline values. After captopril discontinuation, proteinuria increased significantly ( Table 2) . independent of systemic blood pressure changes and was not accompanied by modifications in renal other hand, some patients with low or negative urinary function. excretions of C5b-9 had a poor antiproteinuric
We found a remarkable variability in the antiproresponse ( Figure 1) . teinuric response to captopril ( Figure 1) ; some patients Baseline urinary C5b-9 values of patients with MGN showed proteinuria reductions higher than 65% of the showed a significantly positive correlation with baseline baseline values, whereas in other patients the antiproproteinuria excretions (r=0.60, P<0.05) ( Figure 2 ). teinuric effect was totally absent. The reasons for these Urinary C5b-9 levels measured after 8 weeks of captop-discrepancies remain unexplained. A theoretical posril treatment decreased from 89±23 ng/mg UCr to sibility is that ongoing immune-complex formation 73±25 ng/mg UCr, with no statistical significance would influence the response. If this hypothesis is ( Table 2 ). However, similar to the baseline values, a correct, urinary C5b-9 levels should serve as a predictor significantly positive correlation between C5b-9 levels of antiproteinuric effect of ACE inhibitors. However, and proteinuria excretion was found at +8 week (r= our study clearly shows that some patients with very 0.77, P<0.05) (see Figure 2) . high urinary C5b-9 levels have marked decreases in proteinuria with captopril ( Figure 1 ) while other patients with negative or very low urinary C5b-9 levels
Discussion
did not respond to this treatment.
In conclusion, our study shows that urinary C5b-9 Several experimental and clinical studies have shown excretion does not predict the antiproteinuric response that urinary C5b-9 levels are frequently increased in to ACE inhibitors.
